In today’s challenging economic climate, small businesses are constantly battling financial obstacles. Lead Sensei, under the leadership of CEO Daniel Bradley, is stepping in as a ...
After already halving its workforce twice since 2022, Sensei Therapeutics is forging ahead with another deep round of cuts. The biotech on Friday said 65% of its staffers are set to leave the company.
The average one-year price target for Sensei Biotherapeutics (NasdaqCM:SNSE) has been revised to $51.00 / share. This is an increase of 53.85% from the prior estimate of $33.15 dated November 7, 2025.
Sensei Biotherapeutics, Inc. announced key updates regarding its lead program, solnerstotug (SNS-101), a treatment targeting the immune checkpoint VISTA in advanced solid tumors. The company ...
Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its immune checkpoint inhibitor through phase 2. The asset in question, dubbed ...
BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics ...
With living urban spaces shrinking as the world's population increases, it seems the concept of dual-purpose furniture and fittings is heading towards the mainstream. Joining the likes of the sofa bed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results